Clinical Trial Update: Managed Access Programs for BYL719, Alpelisib

View source ↗

Summary

Novartis' alpelisib (BYL719) is available through managed access programs for PIK3CA-Related Overgrowth Spectrum and breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Pik3ca-related Overgrowth Spectrum

Drugs mentioned

• alpelisib (BYL719) (alpelisib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS), Breast Cancer | Status: AVAILABLE